Investors / Brandon BioCatalyst
Brandon BioCatalyst
Venture capital
Brandon BioCatalyst is an Australasian life science investment fund managed by Brandon Capital that supports the development and commercialisation of early-stage biomedical discoveries from member research organisations. It is a collaboration of investors, CSL, governments and more than 50 medical research institutes and hospitals, providing capital and expertise to develop new therapies.
Invests inHealthcare & Biotech
In its own wordsbiotechlife sciencestherapeuticsmedical researchhealthcarecommercialisation
Your fit with Brandon BioCatalyst
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsBrandon BioCatalyst lists 21 checked portfolio companies on its own site. Its largest theme is Healthcare & Biotech (100%). 60% of its companies are based in Australia. It invests most often alongside Brandon Capital, Stoic VC and Uniseed.
No funding round on record names Brandon BioCatalyst yet, so the figures come from its portfolio page.
Round figures show recent activity, not Brandon BioCatalyst's whole history. Rounds on record name 0 companies; its own site lists 21. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 53th | 21 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 84th | 6 countries |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers21100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Brandon BioCatalyst head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
21 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Allay Therapeutics develops technology for localized pain management. | Healthcare & Biotech | Portfolio page | ||
| Aravax is dedicated to developing next-generation immunotherapies for the treatment of food allergy | Healthcare & Biotech | Portfolio page | ||
| Azura Ophthalmics develops treatments for ophthalmic conditions using keratolytics | Healthcare & Biotech | Portfolio page | ||
| CatalYm is developing a safe and efficacious immune therapy for solid tumors. | Healthcare & Biotech | Portfolio page | ||
| Certa Therapeutics develops precision therapies for patients with inflammatory and fibrotic diseases | Healthcare & Biotech | Portfolio page | ||
| Cincera Therapeutics is a privately held biotechnology company focused on the discovery and development of new drugs aiming to treat inflammatory and fibrotic conditions associated with metabolic diseases. | Healthcare & Biotech | Portfolio page | ||
| Currus Biologics is developing its proprietary BEAT technology for solid tumours | Healthcare & Biotech | Portfolio page | ||
| Denteric is developing a novel therapy called GPV381 for chronic inflammation. | Healthcare & Biotech | Portfolio page | ||
| EBR Systems develops and manufactures a leadless left ventricular endocardial pacing device for heart failure treatment. | Healthcare & Biotech | Portfolio page | ||
| ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defense enhancers for the prevention of severe complications from respiratory viral infections in vulnerable populations. | Healthcare & Biotech | Portfolio page | ||
| George Medicines develops single-pill combination therapies for non-communicable diseases | Healthcare & Biotech | Portfolio page | ||
| Glyscend develops oral pill therapies to treat Type 2 Diabetes and Obesity by mimicking the effect of bariatric surgery | Healthcare & Biotech | Portfolio page | ||
| MycRx is developing oral, small molecule inhibitors that directly target Myc, oncology's 'mega target' | Healthcare & Biotech | Portfolio page | ||
| NRG Therapeutics is developing innovative oral medicines for amyotrophic lateral sclerosis and Parkinson's | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| OncoRes Medical is developing an intraoperative imaging technology to provide surgeons with real-time assessment of tissue microstructure. | Healthcare & Biotech | Portfolio page | ||
| Pathios Therapeutics is a clinical-stage oncology and immunology company that targets the acid-sensing GPCR, GPR65, to transform cancer outcomes | Healthcare & Biotech | Portfolio page | ||
| Pheon Therapeutics is developing next generation Antibody-Drug Conjugates for a wide range of hard-to-treat cancers | Healthcare & Biotech | Portfolio page | ||
| PolyActiva develops biodegradable implants for sustained drug delivery to treat ophthalmic diseases | Healthcare & Biotech | Portfolio page | ||
| Q-Sera develops and manufactures blood collection tubes that rapidly produce high-quality serum for biochemical analysis. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- brandonbiocatalyst.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Companies checked
- 21
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Brandon BioCatalyst's profile as data
Pull Brandon BioCatalyst's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/brandonbiocatalyst.com
# also
GET /v1/firms/brandonbiocatalyst.com/portfolio
GET /v1/firms/brandonbiocatalyst.com/coinvestors
GET /v1/firms/brandonbiocatalyst.com/news